0001209191-18-059793.txt : 20181121 0001209191-18-059793.hdr.sgml : 20181121 20181121172948 ACCESSION NUMBER: 0001209191-18-059793 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181112 FILED AS OF DATE: 20181121 DATE AS OF CHANGE: 20181121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAPADOPOULOS STELIOS CENTRAL INDEX KEY: 0001202098 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 181198872 MAIL ADDRESS: STREET 1: 3 SOMERSET DRIVE SOUTH CITY: GREAT NECK STATE: NY ZIP: 11020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-11-12 0 0001505512 Regulus Therapeutics Inc. RGLS 0001202098 PAPADOPOULOS STELIOS C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121 1 0 0 0 Common Stock 2018-11-12 4 A 0 20910 A 168672 D Stock Option (Right to Buy) 31.92 2018-11-12 4 D 0 152 D 2022-02-08 Common Stock 152 0 D Stock Option (Right to Buy) 111.84 2018-11-12 4 D 0 1458 D 2023-06-09 Common Stock 1458 0 D Stock Option (Right to Buy) 74.64 2018-11-12 4 D 0 1458 D 2024-05-21 Common Stock 1458 0 D Stock Option (Right to Buy) 120.24 2018-11-12 4 D 0 1458 D 2025-06-08 Common Stock 1458 0 D Stock Option (Right to Buy) 74.40 2018-11-12 4 D 0 3051 D 2026-05-31 Common Stock 3051 0 D Stock Option (Right to Buy) 17.40 2018-11-12 4 D 0 2500 D 2027-05-30 Common Stock 2500 0 D Stock Option (Right to Buy) 8.52 2018-11-12 4 D 0 6250 D 2028-05-16 Common Stock 6250 0 D Stock Option (Right to Buy) 8.76 2018-11-12 4 D 0 4583 D 2028-05-31 Common Stock 4583 0 D On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date. Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018. The shares subject to the cancelled option were fully vested. On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I. The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant. The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first. Christopher Aker, Attorney in Fact 2018-11-13